Xipere (Pf) (triamcinolone acetonide/PF)

The nasal aqueous suspension spray pump delivers about 55 mcg of triamcinolone acetonide per metered spray.

Triamcinolone acetonide is administered by nasal inhalation as an aqueous suspension using a spray pump. Patients should be carefully instructed in the use of the nasal inhalation spray pump, including the need to prime the pump prior to first use and after a period of nonuse (i.e., 2 weeks or more).

Prior to administration of the nasal suspension, patients should be instructed to shake the container well. Patients should gently blow the nose to clear their nasal passages. Patients should tilt the head slightly backward and insert the spray tip into one nostril, pointing the tip toward the back of the nose. The drug suspension should be sprayed into one nostril while holding the other nostril closed and concurrently inspiring through the nose. This procedure should be repeated for the other nostril. Patients should avoid blowing the nose for 15 minutes after inhalation.

No dosing information is available for this tab.

No dosing information is available for this tab.

There is no enhanced messaging for this drug.

There are no contraindication interactions for this drug.

There are no severe interactions for this drug.

There are no moderate interactions for this drug.

Known hypersensitivity to triamcinolone acetonide or any ingredient in the respective formulations.

• Cerebral malaria
• Fungal infection of eye
• Herpes zoster keratitis
• Herpes zoster keratoconjunctivitis
• Ocular herpes simplex
• Tuberculosis of the eye

• Cataracts
• Ocular hypertension
• Viral ocular infection

• Diabetes mellitus
• Glaucoma

Adverse effects occurring in at least 2% of adults and children 12 years of age or older receiving triamcinolone acetonide nasal aqueous suspension in clinical trials and more frequently than with placebo included pharyngitis, epistaxis, and increased cough.

Adverse effects occurring in more than 2% of children 4-12 years of age receiving triamcinolone acetonide nasal aqueous suspension in clinical trials and more frequently than with placebo included flu syndrome, increased cough, pharyngitis, bronchitis, dyspepsia, and tooth disorder.

Adverse effects occurring in at least 2% of children 2-5 years of age receiving triamcinolone acetonide nasal aqueous suspension in one study and more frequently than with placebo included headache, pharyngolaryngeal pain, epistaxis, nasopharyngitis, upper abdominal pain, diarrhea, asthma, rash, excoriation, and rhinorrhea.

More Frequent

• Cataracts

Less Frequent

• Endophthalmitis
• Glaucoma
• Infection
• Ocular infection

Rare or Very Rare

• Allergic dermatitis
• Conjunctival hemorrhage
• Depression
• Diabetes mellitus
• Drug-induced psychosis
• Gastrointestinal hemorrhage
• Hypercortisolism
• Hypokalemia
• Hypopyon
• Hypothalamic-pituitary insufficiency
• Myopathy
• Osteoporosis
• Peptic ulcer
• Retinal detachment
• Skin rash

More Frequent

• Ocular hypertension

Less Frequent

• Blurred vision
• Increased appetite
• Ocular discomfort

Rare or Very Rare

• Euphoria
• Gastric acid hypersecretory conditions
• Hirsutism
• Insomnia
• Irregular menstrual periods
• Mood changes
• Ocular inflammation
• Personality disorders
• Reduced visual acuity
• Skin hypopigmentation
• Vitreous floater

No enhanced messaging available.

Safety and efficacy of intranasal triamcinolone acetonide suspension have not been established in children younger than 2 years of age. Intranasal corticosteroids may cause a reduction in growth velocity in pediatric patients.

Category C. Hypoadrenalism may occur in infants born to women receiving corticosteroids during pregnancy; these infants should be monitored carefully.

Not known whether triamcinolone acetonide is distributed into milk. Caution is advised if the drug is administered in nursing women.

Experience from clinical trials in those 65 years of age or older is insufficient to determine whether they respond differently from younger adults. Based on other reported clinical experience to date, no substantial differences in safety and efficacy relative to younger adults is apparent.